A personalized approach to acute myeloid leukemia therapy: current options

Szczegóły
Opis

Tytuł:: A personalized approach to acute myeloid leukemia therapy: current options
Autorzy:: Illangeswaran RSS
Das S
Paul DZ
Mathews V
Balasubramanian P
Temat:: Acute myeloid leukemia
personalized medicine
chemotherapy
molecular markers
Therapeutics. Pharmacology
RM1-950
Źródło:: Pharmacogenomics and Personalized Medicine, Vol Volume 12, Pp 167-179 (2019)
Wydawca:: Dove Medical Press, 2019.
Rok publikacji:: 2019
Kolekcja:: LCC:Therapeutics. Pharmacology
Typ dokumentu:: article
Opis pliku:: electronic resource
Język:: English
ISSN:: 1178-7066
Relacje:: https://www.dovepress.com/a-personalized-approach-to-acute-myeloid-leukemia-therapy-current-opti-peer-reviewed-article-PGPM; https://doaj.org/toc/1178-7066
Dostęp URL:: https://doaj.org/article/9c453c5e907d4cd891a810fcfd90e45e Link otwiera się w nowym oknie
Numer akcesji:: edsdoj.9c453c5e907d4cd891a810fcfd90e45e
: Czasopismo naukowe

Full Text Finder

Raveen Stephen Stallon Illangeswaran, Saswati Das, Daniel Zechariah Paul, Vikram Mathews, Poonkuzhali BalasubramanianDepartment of Haematology, Christian Medical College, Vellore, IndiaAbstract: Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, including midostaurin, enasidenib, ivosidenib, gemtuzumab–ozogamicin, and CPX351 by the US Food and Drug Administration has widened the treatment options for clinicians treating AML. This review focuses on some of these novel therapies and other promising agents under development, along with key clinical trial findings in AML.Keywords: acute myeloid leukemia, personalized medicine, chemotherapy, molecular markers

Informacja